Resistance development after long-term sorafenib exposure in hepatocellular cancer cell lines and risk of rebound growth and epithelial to mesenchymal transition.
Chris Verslype
Research Funding - Bayer Schering Pharma
Hannah van Malenstein
No relevant relationships to disclose
Jeroen Dekervel
No relevant relationships to disclose
Petra Windmolders
No relevant relationships to disclose
Louis Libbrecht
No relevant relationships to disclose
Rudy van Eijsden
No relevant relationships to disclose
Frederik Nevens
No relevant relationships to disclose
Jos van Pelt
No relevant relationships to disclose